SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-271109
Filing Date
2020-10-16
Accepted
2020-10-16 16:16:02
Documents
16
Period of Report
2020-10-14
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d884629d8k.htm   iXBRL 8-K 36206
2 EX-4.1 d884629dex41.htm EX-4.1 69198
3 EX-5.1 d884629dex51.htm EX-5.1 8430
4 EX-10.1 d884629dex101.htm EX-10.1 135441
8 GRAPHIC g884629g29c52.jpg GRAPHIC 3302
  Complete submission text file 0001193125-20-271109.txt   443599

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA xfor-20201014.xsd EX-101.SCH 3071
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE xfor-20201014_lab.xml EX-101.LAB 18889
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE xfor-20201014_pre.xml EX-101.PRE 11861
9 EXTRACTED XBRL INSTANCE DOCUMENT d884629d8k_htm.xml XML 3475
Mailing Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134
Business Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134 857-529-8300
X4 Pharmaceuticals, Inc (Filer) CIK: 0001501697 (see all company filings)

IRS No.: 273181608 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38295 | Film No.: 201244211
SIC: 2836 Biological Products, (No Diagnostic Substances)